EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Potential impact of measures to minimise costs of pharmaceutical provision in the province of Toledo


Atencion Primaria 33(3): 126-130
Potential impact of measures to minimise costs of pharmaceutical provision in the province of Toledo
To analyze the potential saving in the pharmaceutical cost that would suppose the use of equivalent pharmaceutical specialties and smaller price, in the main groups of pharmaceutical cost in 1998. Pharmacoepidemiologic study of drug utilization and a pharmaeconomic analysis of minimisation costs. Primary care of the province of Toledo. Prescriptions with official medical prescription of the pharmaceutical groups of greater cost during 1998 (peptic antiulcer, hipolipemiants, antagonists of calcium, hipotensors, peripheral vasodilators, macrolids, nonsteroidal antiinflamatories and antirheumatics, antidepressants and bronchodilatadors). Calculation of consumption by means of defined daily doses, cost of treatment to the day and potential saving. The potential saving in 1998 in the province of Toledo was 1405 million pesetas, which supposes 25% of the total amount of the pharmaceutical cost. Omeprazol, ranitidin and enalapril with 44.65, 46.02 and 32.84% of variation between prescribed and the cheapest alternative, were the specialties with a greater potential of saving. The alternative to prescribe equivalent pharmaceutical specialties and of smaller price has a great potential of saving.


Accession: 049966585

PMID: 14987495



Related references

Potential impact of measures to minimize drug costs in Aragon's primary care system. Atencion Primaria 23(6): 352-358, 1999

Is pharmaceutical innovation declining?: interpreting measures of pharmaceutical innovation and regulatory impact in the USA, 1950-1980. Rational Drug Therapy 17(1): 1-7, 1983

Positive subjective measures in abuse liability studies and real-world nonmedical use: Potential impact of abuse-deterrent opioids on rates of nonmedical use and associated healthcare costs. Journal of Opioid Management 11(3): 199-210, 2015

The impact of the reformation of the public health system of Kazakhstan on the prevalence of the socially significant diseases and pharmaceutical provision of patients. Problemy Sotsial'noi Gigieny, Zdravookhraneniia i Istorii Meditsiny: 44-47, 2009

Provision of a flexible synthetic top landfill liner to minimise leachate production; a case study. Pages 187-198 1988, 1988

Measures of transaction costs in the the Arabica coffee sub-sector in Menoua Division of West Province, Cameroon. 1992

The adoption of pharmaceutical innovation and its impact on the treatment costs for Alzheimer's disease in Taiwan. Journal of Mental Health Policy and Economics 17(3): 107-117, 2015

Social and medical impact, sleep quality and the pharmaceutical costs of heartburn in Taiwan. Alimentary Pharmacology & Therapeutics 22(8): 739-747, 2005

Impact of health service provision on mothers and infants in a rural village in North West Frontier Province, Pakistan. Public Health Nutrition 1(1): 51-59, 1998

Impact of health service provision on mothers and infants in a rural village in North West Frontier Province, Pakistan. Public Health Nutrition 1(1): 51-59, 1999